Western blot analysis showed that the osteosarcoma cells in the IL-6 group exhibited high levels of p-filamin-C, AKT1 and p-extracellular signal-regulated kinase 1/2 (p-ERK1/2), indicating that during rhIL-6 treatment, which results in lobaplatin resistance, elevated AKT1 promotes a high level of p-filamin-C and activates the MAPK signaling pathway (Fig. 6). The gene discussed is AKT1; the disease is osteosarcoma.